公开(公告)号：WO2022049080A1

公开(公告)日：2022-03-10

申请号：PCT/EP2021/074039

申请日：2021-08-31

Applicant: JANSSEN PHARMACEUTICA, N.V.

Inventor： HUBERT, Emma ,  SCRIMGEOUR, Ian ,  RAMOS, David ,  VESOLE, Steven ,  KAPIL, Monica A. ,  GEARY, William C. ,  POPLI, Shagun ,  CANNAMELA, Michael ,  NGUYEN, Jimmy ,  YAN, Hong ,  PÉREZ, Dolores

IPC: A61M5/315 ,  A61M11/00 ,  A61M11/08 ,  A61M15/08 ,  B05B11/02

Abstract: Various exemplary drug syringes with a mechanical stop for a second dose, drug products utilizing the same, and methods of using drug syringes with a mechanical stop for a second dose are provided. In general, a nasal drug delivery device is configured to dispense therefrom first and second doses of a drug therefrom into a nose. The drug delivery device includes a mechanical stop configured to provide a pause between the delivery of the first and second doses. During the pause, a user of the drug delivery device can move the drug delivery device from one nostril, into which the first dose was sprayed, to another nostril, into which the second dose can be sprayed. The mechanical stop is configured to hold the drug delivery device in a static delivery state.

公开(公告)号：WO2011034846A1

公开(公告)日：2011-03-24

申请号：PCT/US2010/048752

申请日：2010-09-14

Applicant: JANSSEN PHARMACEUTICA, N.V. ,  DEMAREST, Keith, T. ,  LENHARD, James, M. ,  LEO, Gregory, C. ,  LIANG, Yin ,  MARTIN, Tonya, L.

Inventor： DEMAREST, Keith, T. ,  LENHARD, James, M. ,  LEO, Gregory, C. ,  LIANG, Yin ,  MARTIN, Tonya, L.

IPC: G01N33/50 ,  A61K49/00

CPC classification number: G01N33/5088 ,  A61K49/0004 ,  Y10T436/142222

Abstract: Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

Abstract translation: 这里提出的是在体内使用α-甲基葡糖苷（AMG）作为胃肠道（GI）系统葡萄糖吸收的指示剂或口服AMG后尿液中的葡萄糖排泄的方法。 该方法可用于例如但不限于确定动物中钠依赖性葡萄糖转运蛋白（SGLT）抑制剂的作用，比较动物中第一和第二SGLT抑制剂的作用的差异，以及 诊断与胃肠道（GI）系统的葡萄糖吸收相关的疾病或来自动物的肾脏的葡萄糖排泄。

公开(公告)号：WO2010093341A1

公开(公告)日：2010-08-19

申请号：PCT/US2008/071294

申请日：2009-02-10

Applicant: JANSSEN PHARMACEUTICA N.V. ,  MACIELAG, Mark, J. ,  WEIDNER-WELLS, Michele, A. ,  LIN, Shu-Chen

Inventor： MACIELAG, Mark, J. ,  WEIDNER-WELLS, Michele, A. ,  LIN, Shu-Chen

IPC: C07D498/04 ,  C07D519/00 ,  A61K31/553 ,  A61P31/00

CPC classification number: C07D498/04 ,  C07D519/00

Abstract: The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

Abstract translation: 本发明涉及可用作抗微生物化合物的C-7异恶唑基喹啉/萘啶衍生物，包含所述衍生物的药物组合物以及所述衍生物和药物组合物作为抗病原微生物，特别是抗性微生物的抗微生物剂的用途。

公开(公告)号：WO2009089235A1

公开(公告)日：2009-07-16

申请号：PCT/US2009/030250

申请日：2009-01-07

Applicant: JANSSEN PHARMACEUTICA N.V. ,  ABDEL-MAGID, Ahmed F. ,  MEHRMAN, Steven J. ,  FERRARO, Caterina

Inventor： ABDEL-MAGID, Ahmed F. ,  MEHRMAN, Steven J. ,  FERRARO, Caterina

IPC: A61K31/381 ,  A61P25/08 ,  C07C307/06 ,  C07D307/81 ,  C07D209/14 ,  C07D409/12 ,  C07D333/58

CPC classification number: C07D409/12 ,  C07C307/06 ,  C07D209/14 ,  C07D307/81 ,  C07D333/58

Abstract: The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.

Abstract translation: 本发明涉及制备用于治疗癫痫和相关疾病的磺酰胺衍生物的新方法。

公开(公告)号：WO2009079597A1

公开(公告)日：2009-06-25

申请号：PCT/US2008/087261

申请日：2008-12-17

Applicant: JANSSEN PHARMACEUTICA N.V. ,  CHAI, Wenying ,  JABLONOWSKI, Jill, A. ,  RUDOLPH, Dale, A. ,  SHAH, Chandravadan, R. ,  SWANSON, Devin, M. ,  WONG, Victoria

Inventor： CHAI, Wenying ,  JABLONOWSKI, Jill, A. ,  RUDOLPH, Dale, A. ,  SHAH, Chandravadan, R. ,  SWANSON, Devin, M. ,  WONG, Victoria

IPC: C07D213/38 ,  C07D233/64 ,  C07D239/26 ,  C07D263/16 ,  C07D263/32 ,  C07D263/56 ,  C07D271/06 ,  C07D271/10 ,  C07D277/28 ,  C07D277/64 ,  C07D307/14 ,  C07D307/54 ,  C07D333/20 ,  C07D413/04 ,  C07D413/12

CPC classification number: C07D271/06 ,  C07D213/38 ,  C07D233/64 ,  C07D239/26 ,  C07D263/16 ,  C07D263/32 ,  C07D263/56 ,  C07D271/10 ,  C07D277/28 ,  C07D277/64 ,  C07D295/073 ,  C07D295/135 ,  C07D295/15 ,  C07D295/155 ,  C07D307/14 ,  C07D307/54 ,  C07D333/20 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and / or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor.

Abstract translation: 本发明涉及可用作NPY Y2受体的抑制剂的式（II）的哌啶基和哌嗪基衍生物，包含所述化合物的药物组合物，所述化合物的制备方法和所述化合物用于治疗和/或预防的用途 由NPY Y2受体介导的疾病，疾病和病症。

公开(公告)号：WO2009079001A1

公开(公告)日：2009-06-25

申请号：PCT/US2008/013810

申请日：2008-12-16

Applicant: JANSSEN PHARMACEUTICA N.V. ,  KINDRACHUK, David, E. ,  VENABLE, Jennifer, D.

Inventor： KINDRACHUK, David, E. ,  VENABLE, Jennifer, D.

IPC: A01N43/40

CPC classification number: C07D401/14 ,  C07D403/04 ,  C07D471/04 ,  C07D491/056 ,  C07D513/04

Abstract: Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H 4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

Abstract translation: 描述了双环杂芳基取代的咪唑化合物，其可用作H 4受体调节剂。 这样的化合物可以用于调节组胺H 4受体活性的药物组合物和方法，以及用于治疗由H 4受体活性如过敏，哮喘，自身免疫性疾病和瘙痒症介导的疾病状态，障碍和病症。

公开(公告)号：WO2009074249A1

公开(公告)日：2009-06-18

申请号：PCT/EP2008/010211

申请日：2008-12-03

Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT ,  JANSSEN PHARMACEUTICA N.V. ,  KALLABIS, Harald ,  THIELEMANN, Wolfgang ,  PERZBORN, Elisabeth ,  RÖHRIG, Susanne ,  KUBITZA, Dagmar ,  SPIRO, Theodore ,  HASKELL, Lloyd ,  MAHAL, Jeet

Inventor： KALLABIS, Harald ,  THIELEMANN, Wolfgang ,  PERZBORN, Elisabeth ,  RÖHRIG, Susanne ,  KUBITZA, Dagmar ,  SPIRO, Theodore ,  HASKELL, Lloyd ,  MAHAL, Jeet

IPC: A61K31/5377 ,  A61P7/02 ,  A61P9/00

CPC classification number: A61K31/5377

Abstract: The present invention relates to the use of selective inhibitors of coagulation factor Xa, in particular of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure as well as their use for the preparation of pharmaceutical drugs for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure.

Abstract translation: 本发明涉及凝血因子Xa的选择性抑制剂，特别是式（I）的恶唑烷酮的用途，用于治疗和/或预防与心力衰竭相关的心力衰竭和/或障碍，以及它们用于 制备用于治疗和/或预防与心力衰竭相关的心力衰竭和/或障碍的药物。

公开(公告)号：WO2009067401A1

公开(公告)日：2009-05-28

申请号：PCT/US2008/083764

申请日：2008-11-17

Applicant: JANSSEN PHARMACEUTICA N.V. ,  LETAVIC, Michael A. ,  STOCKING, Emily M.

Inventor： LETAVIC, Michael A. ,  STOCKING, Emily M.

IPC: C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  A61K31/495 ,  A61P25/00

CPC classification number: C07D407/14 ,  C07D401/14 ,  C07D409/14

Abstract: Certain cycloalkyloxy- and heterocycloalkyloxypyridine compounds are histamine H 3 receptor modulators useful in the treatment of histamine H 3 receptor-mediated diseases.

Abstract translation: 某些环烷氧基和杂环烷氧基吡啶化合物是可用于治疗组胺H3受体介导的疾病的组胺H3受体调节剂。

公开(公告)号：WO2009058801A1

公开(公告)日：2009-05-07

申请号：PCT/US2008/081501

申请日：2008-10-29

Applicant: JANSSEN PHARMACEUTICA, N.V. ,  MANTHEY, Carl L.

Inventor： MANTHEY, Carl L.

IPC: A61K31/4439 ,  A61P35/04

CPC classification number: A61K31/4439

Abstract: The present invention provides therapeutic methods for treating a subject having, and prophylactic methods for preventing in a subject at risk of (or susceptible to ) developing, bone cancer and the bone loss and bone pain associtated with bone cancer, said method comprising the administration of a compound of Formula (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

Abstract translation: 本发明提供了治疗受试者的治疗方法，所述方法具有预防骨骼癌发生（或易于发生）（或易于）发展的受试者和与骨癌相关的骨丢失和骨痛的受试者的预防方法，所述方法包括给予 式（I）的化合物或其溶剂化物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：WO2009058653A1

公开(公告)日：2009-05-07

申请号：PCT/US2008/080915

申请日：2008-10-23

Applicant: JANSSEN PHARMACEUTICA N.V. ,  COATS, Steven J. ,  DYATKIN, Alexey B. ,  HE, Wei ,  LISKO, Joseph ,  MISKOWSKI, Tamara ,  RALBOVSKY, Janet L. ,  SCHULZ, Mark

Inventor： COATS, Steven J. ,  DYATKIN, Alexey B. ,  HE, Wei ,  LISKO, Joseph ,  MISKOWSKI, Tamara ,  RALBOVSKY, Janet L. ,  SCHULZ, Mark

IPC: C07D251/38 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  A61K31/53 ,  A61P1/00

CPC classification number: C07D251/38 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

Abstract translation: 本发明涉及某些新的式（I）化合物：以及制备这些化合物，组合物，中间体及其衍生物以及用于治疗促动蛋白原1或原激素1受体介导的病症的方法。